## Vito Annese

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2434016/publications.pdf

Version: 2024-02-01

7136 17405 24,931 178 63 153 citations h-index g-index papers 185 185 185 28215 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Peroral Endoscopic Myotomy for the Treatment of Esophageal Diverticula. Journal of Clinical Gastroenterology, 2022, 56, 853-862.	1.1	13
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	0.6	120
3	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
4	Comparative efficacy of first-line therapeutic interventions for achalasia: a systematic review and network meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 4305-4314.	1.3	20
5	Prevalence and Predictors of Reduced Bone Density in Child and Adolescent Patients With Crohn's Disease. Journal of Clinical Densitometry, 2021, 24, 252-258.	0.5	2
6	Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Annals of Gastroenterology, 2021, 34, 370-377.	0.4	1
7	Systematic review with metaâ€analysis: safety and tolerability of immune checkpoint inhibitors in patients with preâ€existing inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2021, 53, 374-382.	1.9	54
8	Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110653.	1.4	9
9	TDM of Anti-TNF Agents: The Importance of Being Active!. Inflammatory Bowel Diseases, 2020, 26, 271-272.	0.9	O
10	IBD and malignancies: The gender matters. Digestive and Liver Disease, 2020, 52, 156-157.	0.4	1
11	Genetics and epigenetics of IBD. Pharmacological Research, 2020, 159, 104892.	3.1	74
12	Small Bowel Adenocarcinoma in Crohn's Disease: An Underestimated Risk?. Journal of Crohn's and Colitis, 2020, 14, 285-286.	0.6	4
13	A further "stri(v)de―in IBD management. Digestive and Liver Disease, 2020, 52, 721-722.	0.4	O
14	Global variability of the human IgG glycome. Aging, 2020, 12, 15222-15259.	1.4	37
15	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World Journal of Gastroenterology, 2020, 26, 6710-6769.	1.4	12
16	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	0.9	51
17	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	0.6	958
18	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	0.6	250

#	Article	IF	Citations
19	An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs, 2019, 7, 295-304.	0.5	1
20	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.4	36
21	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
22	Biosimilars in IBD: Similarity Breeds Contented Patients. Digestive Diseases and Sciences, 2019, 64, 1399-1400.	1.1	0
23	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€~AGED' study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	0.8	14
24	Computed tomography or contrastâ€enhanced ultrasonography for followâ€up of liver metastases after Cyberknife therapy?: A prospective pilot study. Journal of Ultrasound in Medicine, 2019, 38, 649-655.	0.8	2
25	A review of extraintestinal manifestations and complications of inflammatory bowel disease. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 66.	0.3	38
26	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. Journal of Crohn's and Colitis, 2018, 12, 687-694.	0.6	10
27	Authors' answers on comment of Abellona et al. on Metabolomic analysis for noninvasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C. Digestive and Liver Disease, 2018, 50, 210-211.	0.4	0
28	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 1334-1342.e4.	0.6	331
29	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	0.6	116
30	Plasma N-Glycan Signatures Are Associated With Features ofÂlnflammatory Bowel Diseases. Gastroenterology, 2018, 155, 829-843.	0.6	80
31	Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. Clinical Epigenetics, 2018, 10, 75.	1.8	32
32	European Crohn's and Colitis Organisation Topical Review on environmental factors in IBD. Journal of Crohn's and Colitis, 2017, 11, jjw223.	0.6	27
33	Alleleâ€specific transcriptional activity of the variable number of tandem repeats of the inducible nitric oxide synthase gene is associated with idiopathic achalasia. United European Gastroenterology Journal, 2017, 5, 200-207.	1.6	17
34	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.4	42
35	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.4	47
36	Genetic risk variants as therapeutic targets for Crohn's disease. Expert Opinion on Therapeutic Targets, 2017, 21, 381-390.	1.5	2

#	Article	IF	Citations
37	Metabolomic analysis with $1\mathrm{H}\text{-NMR}$ for non-invasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C. Digestive and Liver Disease, 2017, 49, 1338-1344.	0.4	7
38	The PROSIT-BIO Cohort. Inflammatory Bowel Diseases, 2017, 23, 233-243.	0.9	116
39	Crohn's Colitis: Development of a multiplex gene expression assay comparing mRNA levels of susceptibility genes. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 435-444.	0.7	2
40	Percutaneous ultrasound-guided fiducial marker placement for liver cancer robotic stereotactic radio-surgery treatment: A comparative analysis of three types of markers and needles. Arab Journal of Gastroenterology, 2017, 18, 83-86.	0.4	5
41	The natural history of Crohn's disease in children: a review of population-based studies. European Journal of Gastroenterology and Hepatology, 2017, 29, 125-134.	0.8	64
42	Prospective Evaluation of Liver Stiffness Using Transient Elastography in Alcoholic Patients Following Abstinence. Alcohol and Alcoholism, 2017, 52, 42-47.	0.9	29
43	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 2017, 11, 3-25.	0.6	1,547
44	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study― Digestive and Liver Disease, 2017, 49, 17-23.	0.4	35
45	CT-P13: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 1653-1661.	2.0	25
46	Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. PLoS ONE, 2017, 12, e0169102.	1.1	17
47	Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World Journal of Gastroenterology, 2017, 23, 197.	1.4	11
48	Percutaneous ultrasound-guided bowel biopsy of a pseudokidney mass. Turkish Journal of Gastroenterology, 2017, 28, 60-62.	0.4	1
49	Disease Course and Colectomy Rate of Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 1945-1953.	0.9	16
50	Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scandinavian Journal of Gastroenterology, 2016, 51, 1193-1199.	0.6	56
51	Pre- and post-procedural quality indicators for colonoscopy: A nationwide survey. Digestive and Liver Disease, 2016, 48, 759-764.	0.4	10
52	Safety profile of methotrexate in inflammatory bowel disease. Expert Opinion on Drug Safety, 2016, 15, 1427-1437.	1.0	21
53	Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Digestive and Liver Disease, 2016, 48, 1432-1437.	0.4	8
54	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nature Communications, 2016, 7, 12342.	5.8	50

#	Article	IF	CITATIONS
55	The genetic burden of inflammatory bowel diseases: implications for the clinic?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1109-1117.	1.4	3
56	The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north–south gradient among Europeans. European Journal of Human Genetics, 2016, 24, 1228-1231.	1.4	21
57	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	0.6	85
58	Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. Journal of Crohn's and Colitis, 2016, 10, 216-225.	0.6	96
59	Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut, 2016, 65, 732-739.	6.1	321
60	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	0.6	577
61	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	6.3	607
62	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
63	Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. GaBI Journal, 2016, 5, 74-83.	0.4	9
64	Biosimilars in Inflammatory Bowel Disease: Angels or Demons?. Gastroenterology & Hepatology (Bartlesville, Okla ), 2016, 5, .	0.0	0
65	Biosimilars in Italy: a gastroenterologist's view. GaBI Journal, 2016, 5, 131-133.	0.4	0
66	Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs, 2015, 3, 87-96.	0.5	2
67	Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	22
68	New endoscopic imaging techniques in surveillance of inflammatory bowel disease. World Journal of Gastrointestinal Endoscopy, 2015, 7, 230.	0.4	13
69	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	9.4	280
70	Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opinion on Emerging Drugs, 2015, 20, 247-261.	1.0	5
71	Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. Chronobiology International, 2015, 32, 903-916.	0.9	50
72	Smoking as an independent determinant of Barrett's esophagus and, to a lesser degree, of reflux esophagitis. Cancer Causes and Control, 2015, 26, 419-429.	0.8	7

#	Article	IF	Citations
73	Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study. American Journal of Gastroenterology, 2015, 110, 708-715.	0.2	48
74	Genetic sharing and heritability of paediatric age of onset autoimmune diseases. Nature Communications, 2015, 6, 8442.	5.8	58
75	Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nature Medicine, 2015, 21, 1018-1027.	15.2	212
76	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2015, 9, 945-965.	0.6	328
77	Gastrointestinal motility disorders in inflammatory bowel diseases. World Journal of Gastroenterology, 2014, 20, 37.	1.4	72
78	Ustekinumab: moving the target from psoriasis to Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2014, 8, 5-13.	1.4	7
79	Capsule endoscopy in Crohn's disease: Is there enough light in the tunnel?. Journal of Crohn's and Colitis, 2014, 8, 1598-1600.	0.6	4
80	Genetic variation in the <i> lymphotoxin-l+ </i> ( <i>LTA</i> )/ <i> tumour necrosis factor-l+ </i> ( <i>TNFl+ </i> ) locus as a risk factor for idiopathic achalasia. Gut, 2014, 63, 1401-1409.	6.1	21
81	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's and Colitis, 2014, 8, 1217-1221.	0.6	53
82	Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. Human Immunology, 2014, 75, 364-369.	1.2	8
83	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Digestive and Liver Disease, 2014, 46, 963-968.	0.4	39
84	HLA-DQA1â€"HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
85	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity, 2014, 47, 287-306.	1.2	16
86	The role of glycosylation in IBD. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 588-600.	8.2	123
87	Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal, 2014, 2, 413-442.	1.6	141
88	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nature Genetics, 2014, 46, 901-904.	9.4	104
89	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1166-1178.	0.6	65
90	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. Journal of Crohn's and Colitis, 2014, 8, 852-858.	0.6	54

#	Article	IF	CITATIONS
91	Is green tea a potential trigger for autoimmune hepatitis?. Phytomedicine, 2013, 20, 1186-1189.	2.3	18
92	Su1762 Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) Immunochip Study. Gastroenterology, 2013, 144, S-470.	0.6	6
93	Outcomes of Treatment for Achalasia Depend on Manometric Subtype. Gastroenterology, 2013, 144, 718-725.	0.6	387
94	European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 982-1018.	0.6	679
95	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology, 2013, 145, 339-347.	0.6	149
96	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72
97	Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 1003-1010.	0.4	4
98	Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors. Digestive and Liver Disease, 2013, 45, 978-985.	0.4	50
99	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
100	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	1.5	185
101	Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?. Clinical and Experimental Gastroenterology, 2013, 6, 1.	1.0	13
102	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e62144.	1.1	75
103	Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	22
104	PPAR <i>î³</i> in Inflammatory Bowel Disease. PPAR Research, 2012, 2012, 1-9.	1.1	54
105	Association Study of a Polymorphism in Clock GenePERIOD3and Risk of Inflammatory Bowel Disease. Chronobiology International, 2012, 29, 994-1003.	0.9	38
106	Hostâ€"microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	13.7	4,038
107	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's and Colitis, 2012, 6, 563-570.	0.6	23
108	Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci. American Journal of Human Genetics, 2012, 90, 636-647.	2.6	290

#	Article	IF	Citations
109	Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia. New England Journal of Medicine, 2011, 364, 1807-1816.	13.9	780
110	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	2.4	316
111	History of cancer in first degree relatives of Barrett's esophagus patients: A case-control study. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 831-838.	0.7	8
112	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseasea~†. Digestive and Liver Disease, 2011, 43, 1-20.	0.4	125
113	Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. Digestive and Liver Disease, 2011, 43, 459-464.	0.4	10
114	Discovering genetic variants in Crohn's disease by exploring genomic regions enriched of weak association signals. Digestive and Liver Disease, 2011, 43, 623-631.	0.4	5
115	Genetics and Ulcerative Colitis: What are the Clinical Implications?. Current Drug Targets, 2011, 12, 1383-1389.	1.0	4
116	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	9.4	1,201
117	Giant esophageal lipoma. Updates in Surgery, 2011, 63, 125-127.	0.9	1
118	RS-SNP: a random-set method for genome-wide association studies. BMC Genomics, 2011, 12, 166.	1.2	1
119	IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Inflammatory Bowel Diseases, 2011, 17, 1832-1833.	0.9	7
120	Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2011, 17, 1834-1835.	0.9	1
121	Genome-Wide Expression Profiling Identifies an Impairment of Negative Feedback Signals in the Crohn's Disease-Associated NOD2 Variant L1007fsinsC. Journal of Immunology, 2011, 186, 4027-4038.	0.4	25
122	A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease. PLoS Genetics, 2011, 7, e1001283.	1.5	187
123	Investigation of Multiple Susceptibility Loci for Inflammatory Bowel Disease in an Italian Cohort of Patients. PLoS ONE, 2011, 6, e22688.	1.1	53
124	Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1108-1117.	0.9	22
125	Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics, 2010, 42, 332-337.	9.4	572
126	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	9.4	2,284

#	Article	IF	Citations
127	An Immunohistochemical Study of the Myenteric Plexus in Idiopathic Achalasia. Journal of Clinical Gastroenterology, 2010, 44, 407-410.	1.1	53
128	Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Human Molecular Genetics, 2010, 19, 2059-2067.	1.4	157
129	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Gastroenterology, 2010, 105, 2218-2227.	0.2	390
130	IL- $1\hat{1}^2$ -511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: An Italian population study and meta-analysis of European studies. Digestive and Liver Disease, 2010, 42, 179-184.	0.4	15
131	Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Digestive and Liver Disease, 2010, 42, 175-178.	0.4	70
132	Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointestinal Endoscopy, 2010, 71, 927-933.	0.5	93
133	Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. American Journal of Gastroenterology, 2009, 104, 2760-2767.	0.2	114
134	Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18680-18685.	3.3	231
135	Association of genetic profiles to Crohn's disease by linear combinations of single nucleotide polymorphisms. Artificial Intelligence in Medicine, 2009, 46, 131-138.	3.8	3
136	Digging out Crohn's disease genes. Inflammatory Bowel Diseases, 2009, 15, 1436-1437.	0.9	0
137	Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nature Genetics, 2009, 41, 216-220.	9.4	364
138	Common variants at five new loci associated with early-onset inflammatory bowel disease. Nature Genetics, 2009, 41, 1335-1340.	9.4	459
139	Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease. American Journal of Human Genetics, 2009, 84, 399-405.	2.6	246
140	High resolution melting (HRM) analysis for the detection of ER22/23EK, Bcll, and N363S polymorphisms of the glucocorticoid receptor gene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 269-274.	1.2	23
141	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. American Journal of Gastroenterology, 2009, 104, 2483-2491.	0.2	37
142	Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1449-1460.	0.9	7
143	Linear IgA bullous dermatosis andÂulcerative colitis treated byÂproctocolectomy. European Journal of Dermatology, 2009, 19, 651-651.	0.3	10
144	Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?. World Journal of Gastroenterology, 2009, 15, 2456.	1.4	21

#	Article	IF	Citations
145	New biologics in the management of Crohn's disease: focus on certolizumab pegol. Clinical and Experimental Gastroenterology, 2009, 2, 61-8.	1.0	3
146	Mucosal NOD2 expression and NF- $\hat{l}^{\circ}B$ activation in pediatric Crohn $\hat{E}^{1}\!\!/\!\!4$ s disease. Inflammatory Bowel Diseases, 2008, 14, 295-302.	0.9	32
147	Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohnʽs disease in an Australian population. Inflammatory Bowel Diseases, 2008, 14, 585-590.	0.9	35
148	Successful induction of clinical response and remission with certolizumab pegol in Crohn $\hat{E}\frac{1}{4}$ s disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	0.9	21
149	Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nature Genetics, 2008, 40, 1211-1215.	9.4	310
150	Risk of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Ways to Prevent It: Old Myths, a Current Need? The Case of Allopurinol. Clinical Gastroenterology and Hepatology, 2008, 6, 374-376.	2.4	5
151	Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. American Journal of Gastroenterology, 2008, 103, 2509-2516.	0.2	66
152	Replication of interleukin 23 receptor and autophagyrelated 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World Journal of Gastroenterology, 2008, 14, 4643.	1.4	66
153	Prediction of Crohn's Disease by Profiles of Single Nucleotide Polymorphisms. Lecture Notes in Computer Science, 2008, , 564-571.	1.0	0
154	Analysis of Candidate Genes on Chromosomes 5q and 19p in Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2007, 45, 180-186.	0.9	18
155	Dissecting genetic predisposition to inflammatory bowel disease: current progress and prospective application. Expert Review of Clinical Immunology, 2007, 3, 287-298.	1.3	7
156	Aberrant DNA Methylation in Non-Neoplastic Gastric Mucosa of H. Pylori Infected Patients and Effect of Eradication. American Journal of Gastroenterology, 2007, 102, 1361-1371.	0.2	173
157	Polymorphisms of Tumor Necrosis Factor-α but Not MDR1 Influence Response to Medical Therapy in Pediatric-Onset Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2007, 44, 171-179.	0.9	76
158	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. American Journal of Gastroenterology, 2007, 102, 601-608.	0.2	95
159	DMBT1 Confers Mucosal Protection In Vivo and a Deletion Variant Is Associated With Crohn's Disease. Gastroenterology, 2007, 133, 1499-1509.	0.6	96
160	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointestinal Endoscopy, 2007, 65, 624-632.	0.5	130
161	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	1.4	19
162	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: A meta-analysis. Inflammatory Bowel Diseases, 2007, 13, 1212-1219.	0.9	35

#	Article	IF	CITATIONS
163	Pediatric onset Crohn $\hat{E}^{1}\!\!/\!\!4$ s colitis is characterized by genotype-dependent age-related susceptibility. Inflammatory Bowel Diseases, 2007, 13, 1509-1515.	0.9	58
164	Genetic Variation in Myosin IXB Is Associated With Ulcerative Colitis. Gastroenterology, 2006, 131, 1768-1774.	0.6	95
165	Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. European Journal of Human Genetics, 2006, 14, 780-790.	1.4	24
166	Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Human Genetics, 2006, 119, 305-311.	1.8	61
167	Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease. Human Mutation, 2006, 27, 778-785.	1.1	47
168	Contribution of IBD5 Locus to Clinical Features of IBD Patients. American Journal of Gastroenterology, 2006, 101, 318-325.	0.2	27
169	Non-surgical treatment of esophageal achalasia. World Journal of Gastroenterology, 2006, 12, 5763.	1.4	42
170	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. Journal of Clinical Gastroenterology, 2005, 39, 291-297.	1.1	59
171	Association of DLG5 R30Q variant with inflammatory bowel disease. European Journal of Human Genetics, 2005, 13, 835-839.	1.4	70
172	The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. Inflammatory Bowel Diseases, 2005, 11, 1-7.	0.9	57
173	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.2	116
174	Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study. American Journal of Gastroenterology, 2005, 100, 1370-1375.	0.2	71
175	CARD15 Genotyping in Inflammatory Bowel Disease Patients by Multiplex Pyrosequencing. Clinical Chemistry, 2003, 49, 1675-1679.	1.5	30
176	Gastric Emptying of Solids in Patients with Nonobstructive Crohn's Disease Is Sometimes Delayed. Journal of Clinical Gastroenterology, 1995, 21, 279-282.	1.1	42
177	Gallbladder function and gastric liquid emptying in achalasia. Digestive Diseases and Sciences, 1991, 36, 1116-1120.	1.1	39
178	Botulinum neurotoxin in the gastrointestinal tract. , 0, , 278-287.		0